Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Neogenomics Inc’s stock clocked out at $8.72, up 12.89% from its previous closing price of $7.72. In other words, the price has increased by $12.89 from its previous closing price. On the day, 4.51 million shares were traded. NEO stock price reached its highest trading level at $8.812 during the session, while it also had its lowest trading level at $7.66.
Ratios:
To gain a deeper understanding of NEO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.58 and its Current Ratio is at 3.92. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.48.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 06 ’25 when Sherman Jeffrey Scott bought 20,000 shares for $5.62 per share. The transaction valued at 112,322 led to the insider holds 188,332 shares of the business.
Zook Anthony P. bought 17,900 shares of NEO for $99,954 on Aug 06 ’25. The Chief Executive Officer now owns 38,066 shares after completing the transaction at $5.58 per share. On May 27 ’25, another insider, Kelly Michael Aaron, who serves as the Director of the company, bought 5,000 shares for $7.60 each. As a result, the insider paid 38,000 and bolstered with 5,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 1156415488 and an Enterprise Value of 1373869696. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.63 while its Price-to-Book (P/B) ratio in mrq is 1.31. Its current Enterprise Value per Revenue stands at 1.993 whereas that against EBITDA is -176.681.
Stock Price History:
The Beta on a monthly basis for NEO is 1.60, which has changed by -0.4532578 over the last 52 weeks, in comparison to a change of 0.17342639 over the same period for the S&P500. Over the past 52 weeks, NEO has reached a high of $19.11, while it has fallen to a 52-week low of $4.72. The 50-Day Moving Average of the stock is 24.14%, while the 200-Day Moving Average is calculated to be -9.60%.
Shares Statistics:
It appears that NEO traded 2.44M shares on average per day over the past three months and 1851790 shares per day over the past ten days. A total of 128.68M shares are outstanding, with a floating share count of 125.06M. Insiders hold about 3.19% of the company’s shares, while institutions hold 97.26% stake in the company. Shares short for NEO as of 1757894400 were 5918913 with a Short Ratio of 2.42, compared to 1755216000 on 5369135. Therefore, it implies a Short% of Shares Outstanding of 5918913 and a Short% of Float of 6.3200004000000005.
Earnings Estimates
At present, 13.0 analysts are actively evaluating the performance of Neogenomics Inc (NEO) in the stock market.The consensus estimate for the next quarter is $0.05, with high estimates of $0.09 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.17 and $0.07 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.2, with 13.0 analysts recommending between $0.32 and $0.08.
Revenue Estimates
In. The current quarter, 13 analysts expect revenue to total $183.85M. It ranges from a high estimate of $185.33M to a low estimate of $181.4M. As of. The current estimate, Neogenomics Inc’s year-ago sales were $167.82MFor the next quarter, 13 analysts are estimating revenue of $189.15M. There is a high estimate of $192.28M for the next quarter, whereas the lowest estimate is $186.4M.
A total of 14 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $725.48M, while the lowest revenue estimate was $717.2M, resulting in an average revenue estimate of $722.46M. In the same quarter a year ago, actual revenue was $660.57MBased on 14 analysts’ estimates, the company’s revenue will be $796.07M in the next fiscal year. The high estimate is $810M and the low estimate is $775.8M.
